Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Efficacy of Dexamethasone Intravitreal Implant in Korea

Trial Profile

Safety and Efficacy of Dexamethasone Intravitreal Implant in Korea

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Feb 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dexamethasone (Primary)
  • Indications Branch retinal vein occlusion; Central retinal vein occlusion
  • Focus Adverse reactions
  • Sponsors Allergan
  • Most Recent Events

    • 12 Jan 2016 Primary end point "Best Corrected Visual Acuity" is now removed so trial focus changed from TU + AR to AR. Also treatment for non-infectious uveitis affecting the posterior segment of the eye is now added so change in inclusion criteria and treatment according to ClinicalTrials.gov record.
    • 22 Jun 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.
    • 30 Sep 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top